Indevus Reports Additional Positive Phase III Trial Data For NEBIDO(R)

Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced additional positive results from its Phase III program for NEBIDO (testosterone undecanoate), a long-acting injectable testosterone therapy under development for the treatment of male hypogonadism. The trial data announced has been filed with the U.S. Food and Drug Administration (FDA) as an addition to data contained in the Company’s existing New Drug Application (NDA) that was originally filed on August 28, 2007.

More: continued here

Filed under: Endocrinology on January 29th, 2008